Sangamo Biosciences, Inc. (SGMO) Posts Q2 EPS Loss of $0.20, Releases FY11 Sales Guidance

Sangamo Biosciences, Inc. (NASDAQ: SGMO) reported Q2 EPS of ($0.20), $0.04 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $2.65 million.

Sangamo Biosciences, Inc. sees FY2011 revenue of $10-$12 million, versus the consensus of $11.03 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones
• Calidi Biotherapeutics (CLDI) Reports Q2 Loss of $2.94